A friend recently shared this personal story with me, in the hopes that it will inspire people to demand price controls on drugs, as well as an end to the Rx profiteering by insurance companies. This is a story about a commonly-prescribed generic drug, levothyroxine, used for hypothyroidism and other thyroid conditions. The fact that [...]
Archive for the ‘Access to Medicines’ Category
Another drug price story that defies logic
Posted in Access to Medicines, Consumer Protection, Economics of Health Care, Ethics, Health Care Marketing, Health Insurance on 15 December 2010 | Leave a Comment »
Selling Sickness Conference
Posted in Access to Medicines, Consumer Protection, Economics of Health Care, Ethics, Global Health, Health Care Marketing, Promotions on 11 October 2010 | 1 Comment »
The first international “Selling Sickness” Conference held October 7-8 in Amsterdam drew some 200 participants from around the globe to discuss the issues and trends in marketing of prescription drugs. While most attendees were from Europe, all regions of the world were represented at the event. Slide shows of the presentations, along with a list [...]
NLARx Alert:Immediate Action Needed to Preserve State Medicaid Prescription Drug Rebates
Posted in Access to Medicines, Economics of Health Care, Health Care Reform, Health Insurance on 27 July 2010 | Leave a Comment »
During the first week of July, an action alert was sent out by the National Legislative Association on Prescription Drug Prices (NLARx) about the need for states to take immediate action on this. The full memo can be read via the link on the Pharmaceuticals and Healthcare Reform page of the NLARx website . Among [...]
More Health Headlines of Note
Posted in Access to Medicines, Assistance, Consumer Protection, Discrimination, Economics of Health Care, Ethics, Health Care Marketing on 3 June 2010 | Leave a Comment »
From Pharmalot, May 24, 2010: Wyeth Marketing Targeted Blacks Illegally: Lawsuit A pair of former hospital sales reps filed a whistleblower suit alleging Wyeth, which is now owned by Pfizer, illegally promoted its Rapamune kidney transplant drug for use with other organs and targeted African-Americans, even though this is a high-risk patient group, according to [...]
In the News, and Why it Matters
Posted in Access to Medicines, Assistance, Cause Marketing, Consumer Protection, Cord Blood, Economics of Health Care, Ethics, Health Care Marketing, National Marrow Donor Program, Promotions on 1 June 2010 | Leave a Comment »
These news items have as yet not received much attention, but highlight health issues of concern: Asda to sell cancer drugs at cost price Asda is to sell cancer drugs on a not-for-profit basis while thousands of NHS patients continue to be denied medicines that are deemed too expensive. The supermarket giant called on other [...]
In the News
Posted in Access to Medicines, Discrimination, Economics of Health Care, Ethics, Health Care Marketing, Health Care Reform, Health Insurance on 25 April 2010 | Leave a Comment »
Drug Prices Rose 9.1% Last Year, Ahead of Federal Health Overhaul Drug companies sharply raised prices last year, ahead of increased rebates they must pay to Medicaid and other expenses tied to the federal health overhaul passed last month. WellPoint routinely targets breast cancer patients Shortly after they were diagnosed with breast cancer, each of [...]
